Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
2.41 +0.03 (+1.26%) 03/14/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 2.47 +0.06 (+2.49%) 16:44 ET
Quote Overview for Fri, Mar 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.41
Day High
2.48
Open 2.41
Previous Close 2.38 2.38
Volume 6,600 6,600
Avg Vol 46,195 46,195
Stochastic %K 2.26% 2.26%
Weighted Alpha -84.05 -84.05
5-Day Change -0.13 (-5.12%) -0.13 (-5.12%)
52-Week Range 2.35 - 207.33 2.35 - 207.33
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,515
  • Shares Outstanding, K 1,458
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,130 K
  • EBIT $ -25 M
  • EBITDA $ -24 M
  • 60-Month Beta 5.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -4.21
  • Number of Estimates 1
  • High Estimate -4.21
  • Low Estimate -4.21
  • Prior Year -360.51
  • Growth Rate Est. (year over year) +98.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.35 +2.38%
on 03/13/25
Period Open: 3.34
4.00 -39.75%
on 02/28/25
-0.93 (-27.84%)
since 02/14/25
3-Month
2.35 +2.38%
on 03/13/25
Period Open: 4.09
5.49 -56.10%
on 01/07/25
-1.68 (-41.08%)
since 12/13/24
52-Week
2.35 +2.38%
on 03/13/25
Period Open: 186.48
207.33 -98.84%
on 03/18/24
-184.07 (-98.71%)
since 03/14/24

Most Recent Stories

More News
Aptevo to Participate in March Conferences

SEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...

APVO : 2.41 (+1.26%)
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Marvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth

APVO : 2.41 (+1.26%)
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues

APVO : 2.41 (+1.26%)
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise...

APVO : 2.41 (+1.26%)
Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish

The company announced that all patients with acute myeloid leukemia treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.

APVO : 2.41 (+1.26%)
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

SEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology...

APVO : 2.41 (+1.26%)
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Two of three patients achieved both complete remission and MRD-negative status

APVO : 2.41 (+1.26%)
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Powered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers

APVO : 2.41 (+1.26%)
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

SEATTLE, WA / ACCESSWIRE / November 29, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of...

APVO : 2.41 (+1.26%)
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform"...

APVO : 2.41 (+1.26%)

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

3rd Resistance Point 2.53
2nd Resistance Point 2.50
1st Resistance Point 2.46
Last Price 2.41
1st Support Level 2.39
2nd Support Level 2.36
3rd Support Level 2.32

See More

52-Week High 207.33
Fibonacci 61.8% 129.03
Fibonacci 50% 104.84
Fibonacci 38.2% 80.66
Last Price 2.41
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals